
Part 3 – pre surgery office visit, trying on wigs, and the "bye-bye boobies" party
Source: YouTube
Among women with early breast cancer, the presence of circulating tumor cells (cancer cells in the bloodstream) increased the risk of cancer recurrence and shortened survival. These preliminary results were presented at the 2010 San Antonio Breast Cancer Symposium. Among …
A significant proportion of patients with advanced cancers continue to undergo cancer screening, even though screening is unlikely to benefit these patients. These findings were recently reported in the Journal of the American Medical Association. Cancer screening can detect disease …
According to the results of a study conducted at the M. D. Anderson Cancer Center, women who are diagnosed with breast cancer and treated with chemotherapy while pregnant have a better disease free survival (survival without a cancer recurrence or …
Consistent with what has been reported in the United States, use of the Oncotype DX® breast cancer test influenced treatment decisions for early stage breast cancer patients in Spain. These results were presented at the 35th European Society for Medical …
Despite professional recommendations and public support in favor of regular mammography, only about half of US women get an annual mammogram, even if they have insurance to cover the test. These results were presented at the 2010 San Antonio Breast …
It may be safe for breast cancer survivors to lift weights, including upper body exercises, without increasing risk for lymphedema. These results were reported in the Journal of the American Medical Association. Lymphedema refers to swelling of the arm due …
Xgeva™ (denosumab) has been approved by the US Food and Drug Administration (FDA) for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood related) cancers. It is not approved for patients with …
Among women with early, HER2 positive breast cancer, treatment with a combination of HER2 targeted therapies may produce better outcomes than treatment with only a single HER2 targeted therapy. This was the conclusion of two studies presented at the 2010 …
The Oncotype DX® breast cancer test may change treatment decisions for more than a third of women with early, estrogen receptor positive breast cancer. These results were presented at the 2010 San Antonio Breast Cancer Symposium. The Oncotype DX breast …